Open Access<p>Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up</p>
Author(s) -
Alok Chandra,
Ravi Kanth,
Sandeep Thareja
Publication year - 2019
Publication title -
biologics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 38
eISSN - 1177-5491
pISSN - 1177-5475
DOI - 10.2147/btt.s214518
Subject(s) - medicine , biosimilar , ulcerative colitis , regimen , refractory (planetary science) , retrospective cohort study , rescue therapy , adalimumab , single center , infliximab , adverse effect , rheumatoid arthritis , physics , disease , astrobiology
Adalimumab (ADA) is approved for the management of lcerative colitis (UC) not responding to conventional therapy. Use of biologics in resource-constrained settings is very challenging. Currently, real-life data on the safety and efficacy of ADA biosimilar (Exemptia) in steroid-refractory UC patients are limited.